Form 4: INSMED CEO William Lewis Reports Stock Option Exercise and Sales Under 10b5-1 Plan

INSMED Inc.'s Chair and CEO, William Lewis, reported the exercise of stock options and subsequent sales of common stock totaling 12,302 shares, primarily under a pre-arranged Rule 10b5-1 trading plan.

Summary

• William Lewis, Chair and CEO of INSMED Inc. (INSM), reported multiple transactions involving the company's common stock on June 2 and June 3, 2025.
• On June 2, 2025, Mr. Lewis acquired 6,830 shares of Common Stock through the exercise of stock options at an exercise price of $10.85 per share.
• Also on June 2, 2025, Mr. Lewis sold a total of 6,830 shares of Common Stock in three separate transactions at weighted average prices of $70.23, $71.35, and $71.94 per share.
• These transactions on June 2, 2025, were effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2024.
• On June 3, 2025, Mr. Lewis sold an additional 5,472 shares of Common Stock at a price of $71.50 per share.
• The sale on June 3, 2025, was conducted to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.
• Following these transactions, Mr. Lewis directly owns 308,758 shares of Common Stock and indirectly owns 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including option exercises and sales under a pre-arranged trading plan and for tax obligations, which are generally neutral in sentiment and do not indicate a significant shift in company prospects.

Positives

• The exercise of stock options at a significantly lower price ($10.85) compared to the sale prices (ranging from $70.23 to $71.94) indicates a substantial unrealized gain on the options.
• The transactions were largely conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned and systematic approach to stock sales rather than an immediate reaction to market conditions.

Negatives

• The sale of a significant number of shares by a high-ranking insider (Chair and CEO) could be perceived negatively by some investors, even if pre-planned.

Future Outlook

This Form 4 filing is a disclosure of past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transactions on June 2, 2025, were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• The sale on June 3, 2025, was made to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Industry Context

This filing is a routine insider transaction report specific to INSMED Inc. and does not provide broader industry context or trends.

Related Party Transactions

• Indirect beneficial ownership is reported through the Katie Procter Dynasty Trust and the William Lewis Family Legacy Trust, indicating transactions involving family-related entities.

Stakeholder Impact

• Shareholders: The transactions represent a change in insider ownership, which is a standard disclosure. The sales, while pre-planned, reduce the direct stake of the CEO.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

INSMED Inc, INSM, William Lewis, Form 4, insider trading, stock options, stock sale, 10b5-1 plan, CEO, Director, equity transactions